Clinical and laboratory impact of coagulase-negative staphylococci bacteremia in preterm infants

Acta Paediatr. 2000 Jun;89(6):690-3. doi: 10.1080/080352500750044016.

Abstract

A retrospective evaluation of the clinical and laboratory impact of coagulase-negative staphylococci (CONS) bacteremia in preterm infants was carried out. The study population included all preterm infants (n = 31) in whom two or more blood cultures were positive for CONS within a period of 4 d, with negative blood cultures 1 wk before and 1 wk after the CONS bacteremia. Clinical manifestations and the results of laboratory tests 7 d before and after the positive blood cultures, and on the first day of sepsis, were recorded and compared. During CONS bacteremia, the infants demonstrated apnoea and bradycardia (88%) and a need for oxygen (59%) and ventilatory support (69%). Significant laboratory findings were leukopenia below 5,000 cells/mm3 (12%), leukocytosis above 30,000 cells/mm3 (39%), and thrombocytopenia below 150,000/mm3 (25%). These clinical and laboratory manifestations differed significantly during the bacteremia infection compared with the week before and after.

Conclusion: CONS bacteremia is a clinically significant infection in preterm infants, causing episodes of apnoea and bradycardia, and a need for ventilatory support.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia / blood*
  • Bacteremia / complications
  • Bacteremia / therapy
  • Coagulase
  • Gestational Age
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Infant, Premature, Diseases / blood*
  • Infant, Premature, Diseases / physiopathology
  • Infant, Premature, Diseases / therapy
  • Multivariate Analysis
  • Prognosis
  • Respiration, Artificial
  • Retrospective Studies
  • Staphylococcal Infections / blood*
  • Staphylococcal Infections / complications
  • Staphylococcal Infections / therapy
  • Thrombocytopenia / etiology

Substances

  • Anti-Bacterial Agents
  • Coagulase